Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade

Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade

Peripheral-immune-checkpoint blockade (P-ICB) with mAbs to PD-1 (nivolumab and pembrolizumab) or PD-L1 (atezolizumab, durvalumab, avelumab) alone or combination with chemotherapy represents a novel active treatment for mNSCLC patients. However, this therapy can be associated to immune-related advers...

Full description

Bibliographic Details
Main Authors: Valerio Nardone, Rocco Giannicola, Giovanna Bianco, Diana Giannarelli, Paolo Tini, Pierpaolo Pastina, Antonia Consuelo Falzea, Sebastiano Macheda, Michele Caraglia, Amalia Luce, Silvia Zappavigna, Luciano Mutti, Luigi Pirtoli, Antonio Giordano, Pierpaolo Correale
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
bacterial infections
immune-check point blockade
programmed cell death ligand-1
real-world salvage therapy
cell death receptor
prognostic factors of response
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.684110/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.684110/full

Similar Items